StockMarketWire.com - Cell-based medicine company MaxCyte said it had appointed Richard Douglas as a non-executive director.

Douglas had served as senior vice president of corporate development at Genzyme Corporation. He was currently an adviser to RedSky Partners, a Biotechnology-focused advisory firm.


At 2:09pm: [LON:MXCT] MaxCyte Inc share price was 0p at 250p



Story provided by StockMarketWire.com